Compare Microsoft (MSFT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs Recursion Pharmaceuticals Inc — how do they compare? Microsoft trades at $501.82 (market cap $3.76T), while Recursion Pharmaceuticals Inc trades at $3.34 (market cap $1.78B). The key difference: Microsoft is far larger — about 2112.4× Recursion Pharmaceuticals Inc's market cap, and Microsoft pays a 0.72% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| MSFT | RXRX | |
|---|---|---|
Market Cap | $3.76T | $1.78B |
Volume | 36,654,621 | — |
Sector | Technology | Health |
52-Week High | $542.07 | $6.79 |
52-Week Low | $352.83 | $2.84 |
Enterprise Value | $3.74T | $1.30B |
Dividend Yield | 0.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $503.81, up 0.76% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust earnings beats in recent quarters, with Q2 2026 EPS of $4.74 exceeding the $4.24 estimate. Revenue growth is steady, reaching $281.72B in 2025, supported by a net income margin of 40.31%. Analyst consensus is overwhelmingly positive, with 80.49% buy ratings and a $553.70 price target. Recent news highlights AI leadership and Azure momentum, though concerns over capital expenditures persist.
Outlook remains favorable with AI-driven growth and cloud expansion, but risks include high valuation (P/E 28.19) and competitive pressures. Investment opportunity lies in sustained earnings momentum and dividend stability, while volatility from tech sector shifts and macroeconomic factors warrants caution.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
